Arimidex is a powerful and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is mainly produced by converting androstenedione into estrone in the peripheral tissues with the participation of the aromatase enzyme, then estrone is converted to estradiol. A decrease in blood estradiol has a therapeutic effect in women with breast cancer. >>>Buy Arimidex 1 mg<<<In women in the postmenopausal period, Arimidex in a daily dose of 1 mg causes a decrease in the level of estradiol in the blood by 80%, which is confirmed by a highly sensitive analytical test. It does not have progestogen, androgenic or estrogenic activity. At a dose of up to 10 mg / day, it does not affect the secretion of cortisol and aldosterone, including in the standard test with ACTH stimulation. When using anastrozole, replacement administration of corticosteroids is not required. Clinical Efficiency and Safety Common breast cancer First-line therapy for postmenopausal women with advanced breast cancer. Two double-blind controlled clinical trials with a similar design (study 1033IL / 0030 and study 1033IL / 0027) were performed to evaluate the efficacy of Arimidex compared with tamoxifen as a first-line treatment for locally advanced or metastatic breast cancer with positive or unknown receptor rates hormones in women in the postmenopausal period. https://oneanabolic.000webhostapp.com/2020/01/anavar-10-mg-oxandrolone-price In total, 1021 patients were randomized to use Arimidex at a dose of 1 mg once a day or tamoxifen at a dose of 20 mg once a day. The main end results in both studies were time to tumor progression, frequency of objective tumor response, and safety. Evaluation of the main endpoints of study 1033IL / 0030 showed that Arimidex had a statistically significant advantage over tamoxifen in time to tumor progression (risk ratio (RR) 1.42; 95% CI 1.11; 1.82, median time to progression 11, 1 and 5.6 months for Arimidex and tamoxifen, respectively; p = 0.006); the frequency of the objective response of the tumor was the same for Arimidex and tamoxifen. https://oneanabolics.blogspot.com/2020/01/characteristics-anastrozole-1mg.html Study 1033IL / 0027 demonstrated that the frequency of the objective response of the tumor and the time to tumor progression for Arimidex and tamoxifen were similar. Evaluation of the secondary endpoints confirmed the assessment of the main endpoint performance indicators. The rather low mortality rate in the treatment groups of both studies did not allow to draw conclusions about the differences in overall survival rates.
Second-line therapy for postmenopausal women with advanced breast cancer Arimidex was studied in two controlled clinical trials (study 0004 and study 0005) in postmenopausal women with advanced breast cancer, in whom the disease progressed after treatment with advanced breast cancer or breast cancer in the early stages of tamoxifen. http://oneanabolic.com/catalog/product/arimidex In total, 764 patients were randomized to use Arimidex at a dose of 1 mg or 10 mg once a day or megestrol acetate at a dose of 40 mg 4 times a day. The time to progression and the frequency of an objective response were the main indicators of effectiveness. The incidence of prolonged (> 24 weeks) stable disease, the rate of progression, and overall survival were also determined. In both studies, there were no significant differences between treatment groups for any of the efficacy parameters. Adjuvant treatment of invasive breast cancer with a positive hormone receptor in the early stages
In a large phase III study conducted with 9366 postmenopausal women with operable breast cancer, which had been treated for 5 years, Arimidex was statistically superior to tamoxifen in disease-free survival. Significantly more advantages with respect to disease-free survival were noted in favor of Arimidex compared with tamoxifen in a prospectively defined population with positive hormone receptor indices.
0 Comments
Leave a Reply. |
ArchivesCategories |